Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press37810.17650/1726-9776-2014-10-3-49-53DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряImmunohistochemical study in the grading of non-muscle-invasive papillary urothelial carcinoma of the bladderИммуногистохимическое исследование в оценке степени злокачественности немышечно-инвазивного папиллярного уротелиального рака мочевого пузыряPugachevV. V.ПугачевВ. В.
Russian Federation
GorbanN. A.ГорбаньН. А.
Russian Federation
perovanina@mail.ruSafiullinK. N.СафиуллинК. Н.
Russian Federation
KaryakinO. B.КарякинО. Б.
Russian Federation
Medical Radiology Research Center, Ministry of Health of Russia, ObninskФГБУ «Медицинский радиологический научный центр» Минздрава России, Обнинск3009201410349530911201409112014https://oncourology.abvpress.ru/oncur/article/view/378

Tumor grade and pT stage are significant prognostic factors in non-muscle-invasive papillary urothelial bladder carcinoma (BC) therefore  these indicators are of great importance. The purpose of the investigation was to determine whether molecular biological markers (Ki-67 level, p53, CK20, and c-erbB-2 expression) may specify the grade and invasive potential of papillary urothelialBC. The investigators examined the specimens taken after transurethral resection of the bladder from 57 patients (46 men and 11 women) aged 24 to 75 years (mean age 56 ± 1.5 years) with non-muscle-invasive papillary urothelial BC referring to as a moderate and poor prognostic group according to the EORTC scoring system, who had received combined treatment at the Medical Radiology Research Center in 1998 to 2005 (the postoperative follow-up was 2 to 9 years).

Степень злокачественности опухоли и рТ стадия являются важными прогностическими критериями при немышечно-инвазивном папиллярном уротелиальном раке мочевого пузыря (РМП), поэтому имеет большое значение точное определение этих параметров.

Цель исследования – оценка возможности молекулярно-биологических маркеров (уровень Ki-67, экспрессия р53, СК20 и С-erbB-2) в уточнении степени злокачественности и инвазивного потенциала папиллярного уротелиального РМП. Исследован материал после трансуретральной резекции мочевого пузыря (МП) 57 пациентов (46 мужчин и 11 женщин) в возрасте от 24 до 75 лет (средний возраст 56 ± 1,5 года) с немышечно-инвазивным уротелиальным РМП, относящихся к группе промежуточного и неблагоприятного прогноза по балльной системе EORTC, проходивших комбинированное лечение в Медицинском радиологическом научном центре с 1998 по 2005 г. (сроки наблюдения – от 2 до 9 лет после операции).

papillary urothelial carcinomamalignancy gradeр53Ki-67СК20С-erbB-2immunohistochemical examinationпапиллярный уротелиальный ракстепень злокачественностир53Ki-67СК20C-erbB-2иммуногистохимическое исследование1. World Health Organization classification of tumours. Pathology & Genetics: tumours of the urinary system and male genital organs. Lyon, France: IARC Press, 2004.World Health Organization classification of tumours. Pathology & Genetics: tumours of the urinary system and male genital organs. Lyon, France: IARC Press, 2004.2. Simon R., Bürger H., Brinkschmidt C. et al. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol 1998;185(4):345–51.Simon R., Bürger H., Brinkschmidt C. et al. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol 1998;185(4):345–51.3. Клинические рекомендации Европейской ассоциации урологов. М., 2011.Клинические рекомендации Европейской ассоциации урологов. М., 2011.4. Боровиков В.П., Боровиков И.П. Статистический анализ и обработка данных в среде Windows. М., 1998. 592 с.Боровиков В.П., Боровиков И.П. Статистический анализ и обработка данных в среде Windows. М., 1998. 592 с.5. Lopez-Beltran A., Montironi R. Noninvasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004;46(2):170–6.Lopez-Beltran A., Montironi R. Noninvasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004;46(2):170–6.6. Holmäng S., Hedelin H., Anderström C. et al. Recurrence and progression in low grade papillary urothelial tumors. J Urol 1999; 162(3 Pt 1):702–7.Holmäng S., Hedelin H., Anderström C. et al. Recurrence and progression in low grade papillary urothelial tumors. J Urol 1999; 162(3 Pt 1):702–7.7. Quintero A., Alvarez-Kindelan J., Luque R.J. et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006;59(1):83–8.Quintero A., Alvarez-Kindelan J., Luque R.J. et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006;59(1):83–8.8. Compérat E., Camparo P., Haus R. et al. Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases. Virchows Arch 2006;448(3):319–24.Compérat E., Camparo P., Haus R. et al. Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases. Virchows Arch 2006;448(3):319–24.9. Limas C., Bigler A., Bair R. et al. Proliferative activity of urothelial neoplasms: comparison of BrdU incorporation, Ki-67 expression, and nucleolar organiser regions. J Clin Pathol 1993;46(2):159–65.Limas C., Bigler A., Bair R. et al. Proliferative activity of urothelial neoplasms: comparison of BrdU incorporation, Ki-67 expression, and nucleolar organiser regions. J Clin Pathol 1993;46(2):159–65.10. Yin H., Leong A.S. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. Am J Clin Pathol 2004;121(5):679–87.Yin H., Leong A.S. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. Am J Clin Pathol 2004;121(5):679–87.11. Dahse R., Utting M., Werner W. et al. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples. Int J Oncol 2002;20(1):107–15.Dahse R., Utting M., Werner W. et al. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples. Int J Oncol 2002;20(1):107–15.12. Harnden P., Allam A., Joyce A.D. et al. Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease. Histopathology 1995;27(2): 169–74.Harnden P., Allam A., Joyce A.D. et al. Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease. Histopathology 1995;27(2): 169–74.13. Burger M., van der Aa M.N., van Oers J.M. et al. Prediction of progression of non-muscleinvasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: A Prospective Study. Eur Urol 2008;54: 835–44.Burger M., van der Aa M.N., van Oers J.M. et al. Prediction of progression of non-muscleinvasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: A Prospective Study. Eur Urol 2008;54: 835–44.14. Habuchi T., Marberger M., Droller M.J. et al. Prognostic markers for bladder cancer: international consensus panel on bladder tumor markers. Urology 2005;66:64–74. 15. Skagias L., Politi E., Karameris A. et al. Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years' research. J BUON 2009;14(3):457–62.Habuchi T., Marberger M., Droller M.J. et al. Prognostic markers for bladder cancer: international consensus panel on bladder tumor markers. Urology 2005;66:64–74. 15. Skagias L., Politi E., Karameris A. et al. Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years' research. J BUON 2009;14(3):457–62.16. Simonetti S., Russo R., Ciancia G. et al. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Int J Surg Pathol 2009;17(3):198–205.Simonetti S., Russo R., Ciancia G. et al. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Int J Surg Pathol 2009;17(3):198–205.17. Jalali Nadoushan M.R., Taheri T., Jouian N., Zaeri F. Overexpression of HER-2/ neu oncogene and transitional cell carcinoma of bladder. Urol J 2007;4(3):151–4.Jalali Nadoushan M.R., Taheri T., Jouian N., Zaeri F. Overexpression of HER-2/ neu oncogene and transitional cell carcinoma of bladder. Urol J 2007;4(3):151–4.